2016-005252-21: Increasing the amount of pazopanib in the blood by splitting intake moments Verhogen van de hoeveelheid pazopanib in het bloed door het spreiden van inname momenten |
|
|
| Ongoing | 4 | 10 | Europe | Tablet, Votrient | Netherlands Cancer Institute, Netherlands Cancer Institute | Patients for whom pazopanib is considered standard care (advanced renal cell carcinoma and advanced soft-tissue sarcoma). Patiënten voor wie behandeling met pazopanib standaard zorg is (gevorderd renaal cel carcinoom of gevorderd weke delen sarcoom)., Patients with advanced renal cell carcinoma or advanced soft-tissue sarcoma Patiënten met nierkanker of weke delen kanker, Diseases [C] - Cancer [C04] | | | | |
ChiCTR2100044810: A controlled clinical study the combination of first-line immunotherapy and targeted therapy for advanced sarcomatoid renal cell carcinoma |
|
|
| Recruiting | 4 | 40 | | camrelizumab plus Pazopanib Tablets ;Pazopanib Tablets | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Partially self-financing | Advanced sarcomatoid renal cell carcinoma | | | | |
